A groundbreaking treatment for spinal muscular atrophy, the leading genetic cause of infant death, is now accessible to more Australian families. Zolgensma, the therapy, costs $2.5 million per dose, making it the most expensive drug on the pharmaceutical benefits scheme. This treatment has shown extraordinary results in improving conditions for affected children. Eligibility is now expanding from babies up to nine months to children weighing up to 21 kilograms, allowing more children to access this life-changing treatment each year. Health Minister Mark Butler confirmed the treatment was the most expensive on the pharmaceutical benefits scheme, but its one-off course has extraordinary results in improving conditions. The expansion is giving more families hope and the opportunity to decide whether this is the right treatment for their child. Professor Michelle Farrar, a paediatric neurologist, emphasized the importance of early and rapid diagnosis and urgent treatment. Adriana Sharpe, whose daughter received emergency gene therapy at just four weeks old, shared her family's experience, highlighting the life-changing impact of the treatment.
También lo cubren: 7news.com.au - 7NEWS.
🔗 Leer la noticia completa en 7news.com.au - 7NEWS (Australia)
Ver más en NewsToday